Irwin Naturals - Klee Irwin, CEO & Chairman

" Irwin Naturals (CSE:IWIN) acquiring Ketamine Media

Irwin Naturals (IWIN) has agreed to purchase all of the issued and outstanding shares of Ketamine Media. 

" Reunion (TSX:REUN) appoints Greg Mayes as President and CEO

Reunion Neuroscience (REUN) (formerly Field Trip Health Ltd.) has appointed Greg Mayes as President and Chief Executive Officer.

" Psyched Wellness (CSE:PSYC) announces successful pilot run & final flavour profile for Calm

Psyched Wellness (PSYC) has announced positive feedback from a pilot run of 300 bottles of Calm.

" Mindset Pharma (CSE:MSET) signs intellectual property license with Cybin (NEO:CYBN)

Mindset Pharma (MSET) announced a licensing agreement allowing Cybin (CYBN) to acquire intellectual property rights for a subset of Mindset’s preclinical compounds.

" Tryp Therapeutics (CSE: TRYP) applies for 2 new provisional patents

Tryp Therapeutics (TRYP) is filing two new provisional patent applications.

" Lobe Sciences (CSE:LOBE) incorporates Australian subsidiary for psilocin trials

Lobe Sciences (LOBE) has incorporated its wholly-owned Australian subsidiary to facilitate three or more clinical trials.

" Origin Therapeutics’ (CSE:ORIG) Xpira Pharmaceuticals receive FDA approval for psilocybin

Origin Therapeutics’ (ORIG) company, Xpira Pharmaceuticals, receives FDA approval for psilocybin for a trial IND application.
Numinus Wellness - Founder & CEO, Payton Nuquvest

" Numinus (TSX:NUMI) expands ketamine therapy

Numinus Wellness (NUMI) announced the opening of a new clinic in Montreal that will replace an existing downtown clinic.

" Optimi Health (CSE:OPTI), ATMA Journey Centres to proceed with Phase I natural psilocybin and MDMA clinical trial application to Health Canada

Optimi Health (OPTI) has confirmed its intent to proceed with a Phase I clinical trial application (CTA).
Biomind Labs Inc. - CEO, Alejandro Antalich.

" Biomind Labs (NEO:BMND) completes phase II DMT trial

Biomind Labs (BMND) has completed the dose administration for a phase two trial testing its novel DMT drug candidate, BMND01, for treatment-resistant depression.
The Market Herald Video

" Psyence Group (CSE:PSYG) receives Phase IIa clinical trial approval from the UK MHRA

Psyence Group (CSE:PSYG) has received approval for its Phase IIa clinical trial from the Medicines and Healthcare products Regulatory Agency (MHRA).
PsyBio Therapeutics Corp. - CEO, Evan Levine.

" PsyBio (TSXV:PSYB) recieves patent approval

PsyBio Therapeutics (PSYB) has received approval from the United States Patent and Trademark Office for its latest non-provisional patent application.
Numinus Wellness - Founder & CEO, Payton Nuquvest

" Numinus’ (TSX:NUMI) ketamine therapy now available in Toronto

Numinus Wellness’s (NUMI) Neurology Centre in Toronto is now offering ketamine-assisted therapy for patients with neurologic conditions.

" Nova Mentis (CSE:NOVA) completes production of Psilocybin microdose capsules

Nova Mentis (NOVA) has completed the production of psilocybin microdose capsules in partnership with the Toronto Institute of Pharmaceutical Technology (TIPT).
Revitalist Lifestyle and Wellness Ltd. - CEO, Kathryn Walker.

" Revitalist (CSE:CALM) offers psychedelics for veterans

Revitalist Lifestyle and Wellness (CALM) and Wake Network will jointly offer ketamine infusions in the United States and psilocybin clinical retreats internationally.
Goat Industries

" Billy Goat (CSE: GOAT) and FunGuys beverage certification

Billy Goat Brands (GOAT) subsidiary FunGuys Beverages has achieved Phase II certification of TerraCycle’s LOOP testing protocols.

" Origin Therapeutics (CSE:ORIG) appoints new director

Origin Therapeutics Holdings (ORIG) has appointed Michael Galego as a director of the company.

" Lobe Sciences (CSE:LOBE) closes private placement

Lobe Sciences (LOBE) has closed a non-brokered private placement for gross proceeds of $1,347,500.

" Optimi (CSE:OPTI) completes largest legal natural psilocybin harvest in Canadian history

Optimi Health Corp. (OPTI) has completed the largest legal natural psilocybin harvest in Canadian history.

" BetterLife (CSE:BETR) to submit research publication

BetterLife Pharma (BETR) is working on a key research publication on BETR-001, its proprietary 2-bromo-LSD.